{"id":44344,"date":"2025-10-24T23:59:17","date_gmt":"2025-10-24T15:59:17","guid":{"rendered":"https:\/\/flcube.com\/?p=44344"},"modified":"2025-10-24T23:59:18","modified_gmt":"2025-10-24T15:59:18","slug":"alphamab-announces-first-patient-dosed-with-jskn022-a-pd%e2%80%91l1-%ce%b1v%ce%b26-bispecific-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44344","title":{"rendered":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC"},"content":{"rendered":"\n<p>China\u2011based Alphamab Oncology (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) <strong>JSKN022<\/strong> in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-overview\"><strong>Product Overview<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 JSKN022 simultaneously targets <strong>PD\u2011L1<\/strong> and <strong>integrin \u03b1v\u03b26<\/strong> on tumor cells. The ADC is internalized via target\u2011mediated endocytosis; a protease\u2011cleavable linker releases a topoisomerase\u2011I inhibitor, inducing apoptosis.<\/li>\n\n\n\n<li><strong>Dual Immuno\u2011Oncology &amp; ADC Technology<\/strong> \u2013 Built on Alphamab\u2019s proprietary Envafolimab platform, the bispecific format combines immune checkpoint blockade with targeted cytotoxic delivery.<\/li>\n\n\n\n<li><strong>Advanced Chemistry<\/strong> \u2013 Site\u2011specific glycan conjugation and an Alphatecan linker\u2011payload deliver high stability and homogeneity, enhancing therapeutic index.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-highlights\"><strong>Clinical Trial Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design<\/strong> \u2013 Phase\u202fI, open\u2011label, dose\u2011escalation at Sun Yat\u2011sen University Cancer Center.<\/li>\n\n\n\n<li><strong>Population<\/strong> \u2013 Patients with advanced malignant solid tumors expressing either PD\u2011L1 or integrin \u03b1v\u03b26.<\/li>\n\n\n\n<li><strong>Objectives<\/strong> \u2013 Establish safety, tolerability, pharmacokinetics, and preliminary anti\u2011tumor activity.<\/li>\n\n\n\n<li><strong>First\u2011Dose Milestone<\/strong> \u2013 First patient dosed 24\u202fOct\u202f2025; dose\u2011expansion cohorts to begin Q1\u20112026.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\"><strong>Strategic Significance<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class<\/strong> \u2013 Positions Alphamab as a pioneer in bispecific ADCs, expanding the therapeutic landscape for solid tumors.<\/li>\n\n\n\n<li><strong>Bystander Effect &amp; Immune Modulation<\/strong> \u2013 The design allows killing of antigen\u2011negative cells while engaging the immune system via TGF\u2011\u03b2 blockade, potentially overcoming resistance mechanisms.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong> \u2013 Complements Alphamab\u2019s existing ADC portfolio, strengthening its position in the rapidly growing oncology\u2011ADC market.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44345,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,187,16,62,854],"class_list":["post-44344","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-alphamab-oncology","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-9966"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44344\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44344\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:59:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-24T15:59:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\\\/\u03b1v\u03b26 Bispecific ADC\",\"datePublished\":\"2025-10-24T15:59:17+00:00\",\"dateModified\":\"2025-10-24T15:59:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2413.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Alphamab Oncology\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9966\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44344#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44344\",\"name\":\"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\\\/\u03b1v\u03b26 Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2413.webp\",\"datePublished\":\"2025-10-24T15:59:17+00:00\",\"dateModified\":\"2025-10-24T15:59:18+00:00\",\"description\":\"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\\\/\u03b1v\u03b26 bispecific ADC to move into human testing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44344\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2413.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2413.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\\\/\u03b1v\u03b26 Bispecific ADC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44344#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\\\/\u03b1v\u03b26 Bispecific ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44344","og_locale":"en_US","og_type":"article","og_title":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC","og_description":"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.","og_url":"https:\/\/flcube.com\/?p=44344","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:59:17+00:00","article_modified_time":"2025-10-24T15:59:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44344#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44344"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC","datePublished":"2025-10-24T15:59:17+00:00","dateModified":"2025-10-24T15:59:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44344"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44344#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","keywords":["ADC \/ XDC","Alphamab Oncology","Cancer","Clinical trial approval \/ initiation","HKG: 9966"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44344#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44344","url":"https:\/\/flcube.com\/?p=44344","name":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44344#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44344#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","datePublished":"2025-10-24T15:59:17+00:00","dateModified":"2025-10-24T15:59:18+00:00","description":"China\u2011based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of its self\u2011developed bispecific antibody\u2011drug conjugate (ADC) JSKN022 in a Phase\u202fI clinical study (Study No.:\u202fJSKN022\u2011101) at Sun Yat\u2011sen University Cancer Center. This milestone marks the fourth ADC from Alphamab to enter the clinical\u2011trial stage and the world\u2019s first PD\u2011L1\/\u03b1v\u03b26 bispecific ADC to move into human testing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44344#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44344"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44344#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","width":1080,"height":608,"caption":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44344#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Announces First Patient Dosed with JSKN022, a PD\u2011L1\/\u03b1v\u03b26 Bispecific ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2413.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44344"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44344\/revisions"}],"predecessor-version":[{"id":44346,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44344\/revisions\/44346"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}